Use of an h4 agonist molecule to treat acute leukemia
OwnerGaetan TERRASSEinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLEINE or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type B leukemia.
Claims5
A substance having an agonist activity on the histamine H4 receptor to treat acute myeloid leukemia and type T lymphoid leukemia, with the exception of type B leukemia, characterized in that it is made up of an isomer or an isomer mixture of AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1METHOXY-8 METHYL-2METHYLENEDIOXY-6,7 TETRAHYDRO,2,3,4 ISOQUINOLEINE, or tritoqualine.
Dependencies are inferred from the claim text.